An immunoassay for the measurement of sirolimus

Clinical Therapeutics

Volumn 22, Issue SUPPL. B, 2000, Pages

  Jones, Kirsty ^a   Saadat Lajevardi, Soha ^a   Lee, Terry ^a   Horwatt, Ruth ^a   Hicks, David ^b   Johnston, Atholl ^c   Holt, David W ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b PFIZER INC   (United States)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

High performance liquid chromatography; Microparticle enzyme immunoassay; Rapamycin; Sirolimus; Stability; Therapeutic drug monitoring

Indexed keywords

DRUG METABOLITE; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ARTICLE; BLOOD SAMPLING; CALIBRATION; CONTROLLED STUDY; CROSS REACTION; DRUG METABOLISM; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MASS SPECTROMETRY; MICROPARTICLE ENZYME IMMUNOASSAY;

EID: 0034121591     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)89022-0     Document Type: Article

References (22)

1. Sehgal S. Rapamune (sirolimus, rapamycin): An overview and mechanism of action. Ther Drug Monit. 1995;17: 660-665.
2. Yatscoff RW, Aspeslet LJ, Gallant HL. Pharmacodynamic monitoring of immunosuppressive drugs. Clin Chem. 1998; 44:423-432.
3. Sehgal SN. Rapamune® (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998;31:335-340.
4. Kuo CJ, Chung J, Florentino DF, et al. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature. 1992;358:70-73.
5. Calvo V, Crews CM, Vik TA, Bierer BE. Interleukin 2 stimulation of p70 S6 kinase activity is inhibited by the immunosuppressant rapamycin. Proc Natl Acad Sci U S A. 1992;89:7571-7575.
6. Groth CG, Bäckman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation. Transplantation. 1999;67:1036-1042.
7. First MR. Clinical application of immunosuppressive agents in renal transplantation. Surg Clin North Am. 1998; 78:61-76.
8. Kahan BD. Emerging strategies for the clinical application of rapamycin. Clin Biochem. 1998;31:341-344.
9. Johnston A, Holt DW. Therapeutic drug monitoring of immunosuppressant drugs. Br J Clin Pharmacol. 1999;47:339-350.
10. Yatscoff RW, LeGatt D, Keenan R, Chackowsky P. Blood distribution of rapamycin. Transplantation. 1993;56:1202-1206.
11. Yatscoff RW, Boeckx R, Holt DW, et al. Consensus guidelines for therapeutic drug monitoring of rapamycin: Report of the consensus panel. Ther Drug Monit. 1995; 17:676-680.
12. Trepanier DJ, Gallant H, LeGatt D, Yatscoff RW. Rapamycin: Distribution, pharmacokinetics and therapeutic range investigations: An update. Clin Biochem. 1998;31:345-351.
13. Brattström C, Säwe J, Tydén G, et al. Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. Ther Drug Monit. 1997;19:397-406.
14. Yatscoff RW, Faraci C, Bollingbroke P. Measurement of rapamycin in whole blood using reverse-phase high-performance liquid chromatography. Ther Drug Monit. 1992;14:138-141.
15. Napoli KL, Kahan BD. Sample clean up and high performance liquid chromatographic techniques for measurement of whole blood rapamycin concentrations. J Chromatogr B Biomed Appl. 1994;654: 111-120.
16. Napoli KL, Kahan BD. Routine clinical monitoring of sirolimus (rapamycin) whole-blood concentrations by HPLC with ultraviolet detection. Clin Chem. 1996;42:1943-1948.
17. Svensson J, Brattström C, Säwe J. Determination of rapamycin in whole blood by HPLC. Ther Drug Monit. 1997;19:112-116.
18. Streit F, Christians U, Schiebel H, et al. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem. 1996;42:1417-1425.
19. Holt DW, Lee T, Johnston A. Measurement of sirolimus in whole blood using high-performance liquid chromatography with ultraviolet detection. Clin Ther. 2000;22(Suppl B):B38-B48.
20. Beierle FA, Lim HK. A high-performance liquid chromatographic/tandem mass spectrometric method (LC/MS/MS) to quantify rapamycin in whole blood of humans. Data on file. Princeton, NJ: Wyeth-Ayerst Research Laboratories; 1994.
21. Hollis S. Analysis of method comparison studies. Ann Clin Biochem. 1996;33:1-4.
22. Ferron GM, Jusko WJ. Species differences in sirolimus stability in humans, rabbits and rats. Drug Metab Dispos. 1998;26: 83-84.